| Literature DB >> 26846142 |
Xian-Cang Ma1, Zheng Chu2, Xiao-Ling Zhang3, Wen-Hui Jiang1, Min Jia1, Yong-Hui Dang4,5,6, Cheng-Ge Gao7.
Abstract
The present study was designed to construct a recombinant adeno-associated virus (rAAV) which can express NAP in the brain and examine whether this virus can produce antidepressant effects on C57 BL/6 mice that had been subjected to open field test and forced swimming test, via nose-to-brain pathway. When the recombinant plasmid pGEM-T Easy/NT4-NAP was digested by EcoRI, 297 bp fragments can be obtained and NT4-NAP sequence was consistent with the designed sequence confirmed by DNA sequencing. When the recombinant plasmid pSSCMV/NT4-NAP was digested by EcoRI, 297 bp fragments is visible. Immunohistochemical staining of fibroblasts revealed that expression of NAP was detected in NT4-NAP/AAV group. Intranasal delivery of NT4-NAP/AAV significantly reduced immobility time when the FST was performed after 1 day from the last administration. The effects observed in the FST could not be attributed to non-specific increases in activity since intranasal delivery of NT4-NAP/AAV did not alter the behavior of the mice during the open field test. The results indicated that a recombinant AAV vector which could express NAP in cells was successfully constructed and NAP may be a potential target for therapeutic action of antidepressant treatment.Entities:
Keywords: Depression; FST; Intranasal administration; NAP; NT4-NAP/AAV; OFT
Mesh：
Substances：
Year: 2016 PMID： 26846142 DOI： 10.1007/s11064-016-1841-0
Source DB: PubMed Journal: Neurochem Res ISSN： 0364-3190 Impact factor: 3.996